Although the vast majority of advanced pancreatic cancers have a mutated K-ras gene, clinical targeting of K-ras with farnesyl transferase inhibitors has been unsuccessful (SWOG 9924 study). The gene discussed is KRAS; the disease is pancreatic neoplasm.